• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2007年哥本哈根欧洲核医学协会年度大会亮点

Highlights of the annual congress of the European Association of Nuclear Medicine, Copenhagen 2007.

作者信息

Knuuti Juhani, Hustinx Roland

机构信息

Turku PET Centre, Turku University Central Hospital, 20521 Turku, Finland.

出版信息

Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):655-72. doi: 10.1007/s00259-007-0674-0.

DOI:10.1007/s00259-007-0674-0
PMID:18196239
Abstract

INTRODUCTION

The Annual Congress of the European Association of Nuclear Medicine took place in Copenhagen on October 13-17, 2007. The event is the major scientific and professional effort in the field of nuclear medicine in Europe. The most important developments in the fields of instrumentation, radionuclide production, radiochemistry, radiotherapy, as well as the clinical imaging fields of neurology, cardiology, oncology, and general sciences were reported.

OBJECTIVE

This paper emphasizes the major findings and trends at this important gathering. This review is, however, only a brief summary of the large amount of data discussed.

摘要

引言

欧洲核医学协会年会于2007年10月13日至17日在哥本哈根举行。该活动是欧洲核医学领域的主要科学和专业活动。会议报道了仪器设备、放射性核素生产、放射化学、放射治疗以及神经学、心脏病学、肿瘤学和普通科学等临床成像领域的最重要进展。

目的

本文重点介绍了这一重要会议的主要成果和趋势。然而,本综述只是对所讨论的大量数据的简要总结。

相似文献

1
Highlights of the annual congress of the European Association of Nuclear Medicine, Copenhagen 2007.2007年哥本哈根欧洲核医学协会年度大会亮点
Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):655-72. doi: 10.1007/s00259-007-0674-0.
2
Current research in nuclear medicine and molecular imaging in Italy: highlights of the 10th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging.意大利核医学与分子成像领域的当前研究:意大利核医学与分子成像协会第十届全国大会亮点
Q J Nucl Med Mol Imaging. 2011 Jun;55(3):280-300.
3
Highlights of the Annual Congress of the European Association of Nuclear Medicine, Helsinki 2004, and a dash of horizon scanning.2004年赫尔辛基欧洲核医学协会年会亮点及未来趋势展望
Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):113-26. doi: 10.1007/s00259-004-1720-9.
4
Highlights of the Annual Congress of the European Association of Nuclear Medicine, Istanbul, 2005: The incremental value of nuclear medicine for patient management and care.2005年欧洲核医学协会年会亮点:伊斯坦布尔会议——核医学在患者管理与护理中的增量价值
Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):360-81. doi: 10.1007/s00259-006-1986-1.
5
Highlights of the European Association of Nuclear Medicine Congress, Athens, Greece, 30 September to 4 October 2006.2006年9月30日至10月4日于希腊雅典举行的欧洲核医学协会大会亮点
Eur J Nucl Med Mol Imaging. 2007 Feb;34(2):274-93. doi: 10.1007/s00259-006-0327-8.
6
Nuclear medicine 2020.核医学2020年。
Q J Nucl Med Mol Imaging. 2006 Mar;50(1):1-3.
7
Recent advances in nuclear cardiology.核心脏病学的最新进展。
Panminerva Med. 2008 Jun;50(2):105-18.
8
Developments in nuclear cardiology: transition from single photon emission computed tomography to positron emission tomography-computed tomography.核心脏病学的发展:从单光子发射计算机断层扫描到正电子发射断层扫描-计算机断层扫描的转变。
J Invasive Cardiol. 2005 Sep;17(9):491-6.
9
Future of nuclear medicine: SPECT versus PET.核医学的未来:单光子发射计算机断层扫描(SPECT)与正电子发射断层扫描(PET)的比较
J Nucl Med. 2009 Jul;50(7):16N-18N.
10
Evaluating pathology in the brain with nuclear medicine.利用核医学评估脑部病理情况。
Semin Nucl Med. 2008 Jul;38(4):225-6. doi: 10.1053/j.semnuclmed.2008.03.002.

引用本文的文献

1
[F]FDG PET metabolic patterns in mesial temporal lobe epilepsy with different pathological types.[F]不同病理类型的内侧颞叶癫痫的 FDG PET 代谢模式。
Eur Radiol. 2024 Feb;34(2):887-898. doi: 10.1007/s00330-023-10089-1. Epub 2023 Aug 15.
2
Binding of [123I]iodobenzamide to the rat D2 receptor after challenge with various doses of methylphenidate: an in vivo imaging study with dedicated small animal SPECT.用专用小动物 SPECT 研究不同剂量哌甲酯挑战后 [123I]碘苯酰胺与大鼠 D2 受体的结合:一项体内成像研究。
Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):694-701. doi: 10.1007/s00259-010-1668-x. Epub 2010 Nov 26.

本文引用的文献

1
Technetium-binding in labelled HYNIC-peptide conjugates: role of coordinating amino acids.
J Inorg Biochem. 2009 Jul;103(7):971-7. doi: 10.1016/j.jinorgbio.2009.04.007. Epub 2009 May 3.
2
Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET.分化型甲状腺癌的弥漫性亲碘性肺转移:对¹²⁴I PET的挑战
Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):502-8. doi: 10.1007/s00259-007-0601-4. Epub 2007 Nov 20.
3
Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.[90钇-多胺螯合剂]-奥曲肽治疗转移性甲状腺髓样癌可带来长期生存获益:一项II期临床试验
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6696-702. doi: 10.1158/1078-0432.CCR-07-0935.
4
How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies.HYNIC 偶联肽如何结合锝?来自液相色谱 - 质谱联用和稳定性研究的见解。
Dalton Trans. 2007 Nov 21(43):4998-5007. doi: 10.1039/b705111e. Epub 2007 Sep 25.
5
Revised response criteria for malignant lymphoma.恶性淋巴瘤修订后的反应标准。
J Clin Oncol. 2007 Feb 10;25(5):579-86. doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22.
6
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?放射性镓标记的DOTA偶联生长抑素类似物是否优于其他放射性金属标记的同类物?
Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):982-93. doi: 10.1007/s00259-006-0317-x. Epub 2007 Jan 16.
7
18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer.18F-FDG PET是局部晚期直肠癌术前放化疗后肿瘤病理反应的早期预测指标。
J Nucl Med. 2006 Aug;47(8):1241-8.
8
Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.131I-cG250连续两次放射免疫治疗对转移性透明细胞肾细胞癌患者无效。
J Clin Oncol. 2005 Sep 20;23(27):6540-8. doi: 10.1200/JCO.2005.07.732.
9
Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis.结直肠癌肝转移:CT、磁共振成像及PET用于诊断——荟萃分析
Radiology. 2005 Oct;237(1):123-31. doi: 10.1148/radiol.2371042060. Epub 2005 Aug 11.
10
In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker.
Nucl Med Biol. 2005 Jul;32(5):431-6. doi: 10.1016/j.nucmedbio.2005.03.005.